49
Participants
Start Date
July 31, 2011
Primary Completion Date
March 31, 2025
Study Completion Date
March 31, 2025
Idarubicin
"In the phase I study, idarubicin dose is increased step by step as follows: 12 mg/m2/day for 3 days IV in the 1st step; 15 mg/m2/day for 3 days IV in the 2nd step; 18 mg/m2/day for 3 days IV in the 3rd step.~In the phase II study, idarubicin dose is the maximum tolerated dose that is determined from the phase I study or 18 mg/m2/day for 3 days ."
Division of Hematology-Oncology, Konkuk University Medical Center, Seoul
Chung-Ang University Hosptial, Chung-Ang University College of Medicine
OTHER
Seoul National University Hospital
OTHER
Ewha Womans University
OTHER
Samsung Medical Center
OTHER
Chonbuk National University Hospital
OTHER
Pusan National University Hospital
OTHER
Hanyang University Seoul Hospital
OTHER
Soon Chun Hyang University
OTHER
Konkuk University Medical Center
OTHER